SKYE Stock Forecast: Skye Bioscience, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Skye Bioscience, Inc. is $9. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 50 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Skye Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SKYE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SKYE, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2025 | HC Wainwright & Co. | Initiates | Buy | $20 |
| 15 Aug 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 24 June 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 21 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 21 Mar 2025 | Craig-Hallum | Maintains | Buy | — |
| 28 Feb 2025 | William Blair | Initiates | Outperform | — |
| 30 Sept 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Sept 2024 | Piper Sandler | Reiterates | Overweight | — |
| 10 Sept 2024 | JMP Securities | Initiates | Market Outperform | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 6 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 27 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 July 2024 | Craig-Hallum | Initiates | Buy | — |
| 1 July 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 18 June 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 17 June 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 23 May 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 Apr 2024 | Oppenheimer | Initiates | Outperform | — |
| 14 Mar 2024 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SKYE.
This page is one stock. Monday covers all of them.
SKYE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SKYE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −95.1%
- Dividend yield
- —
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Skye Bioscience, Inc. has a market value of $3.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$50.5M.
Diluted earnings per share, trailing twelve months: −$1.27.
Free cash flow in the twelve months to 30 June 2026: −$38.8M.
Skye Bioscience, Inc. employs 2 people.
Data provided by Twelve Data
SKYE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SKYE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Skye Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SKYE
What is the SKYE stock price forecast for 2026-2027?
The median 12-month analyst price target for Skye Bioscience, Inc. is $9, with estimates ranging from $2 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SKYE stock a buy right now?
Of the 2 analysts covering Skye Bioscience, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Skye Bioscience, Inc. 50 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SKYE?
As at 21 Nov 2026, Skye Bioscience, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
Will SKYE stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $9, and Ticker Nerd's factor model ranks Skye Bioscience, Inc. 50 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SKYE stock forecast for 2030?
No analyst covering Skye Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SKYE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $16 over the next 12 months.
What does Skye Bioscience, Inc. do?
Skye Bioscience Inc. is a clinical-stage biotechnology company focused on developing therapies that modulate the endocannabinoid system, with an emphasis on metabolic health and obesity-related conditions. Its current pipeline centers on nimacimab, a peripherally restricted antibody targeting cannabinoid receptor 1, designed to influence pathways involved in fat mobilization, appetite regulation, satiety signaling, and broader metabolic function.
About Skye Bioscience, Inc.
Skye Bioscience Inc. is a clinical-stage biotechnology company focused on developing therapies that modulate the endocannabinoid system, with an emphasis on metabolic health and obesity-related conditions. Its current pipeline centers on nimacimab, a peripherally restricted antibody targeting cannabinoid receptor 1, designed to influence pathways involved in fat mobilization, appetite regulation, satiety signaling, and broader metabolic function. The company also develops ophthalmic programs, including SBI-100 Ophthalmic Emulsion, for eye diseases such as glaucoma and ocular hypertension. Skye Bioscience works across areas including obesity, overweight, metabolic disorders, and select ophthalmology applications, positioning its research around GPCR-based drug development and cannabinoid receptor biology. Headquartered in San Diego, California, Skye Bioscience Inc. operates as a focused biopharmaceutical company advancing targeted, mechanism-based candidates for currently addressed therapeutic markets.
CEO Mr. Punit S. Dhillon B.A. · 2 employees · United States · https://skyebioscience.com